Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02480283|
Recruitment Status : Recruiting
First Posted : June 24, 2015
Last Update Posted : March 28, 2019
|First Submitted Date||May 27, 2015|
|First Posted Date||June 24, 2015|
|Last Update Posted Date||March 28, 2019|
|Actual Study Start Date||November 11, 2015|
|Estimated Primary Completion Date||May 4, 2022 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures
|Original Primary Outcome Measures
|Change History||Complete list of historical versions of study NCT02480283 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures||Not Provided|
|Original Secondary Outcome Measures||Not Provided|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title||Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response|
|Official Title||Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response|
|Brief Summary||This study plans to evaluate the effects of chronic cannabis smoking on lung health by evaluating its effects on pulmonary health, lung physiology and alveolar macrophage function.|
I. Hypotheses and Specific Aims:
With changing legislation, the landscape of cannabis use is shifting; data demonstrates that public perception of marijuana's "safety" has contributed to increasing usage most commonly via the inhaled route (smoking). The effects of habitual cannabis smoking on lung health, however, remains unclear. Spirometric data has been inconclusive regarding risk of airflow limitation and development of chronic obstructive pulmonary disease, a finding that may be attributable to inaccurate reporting due to its former illegal nature. It seems clear, however, that these patients suffer from an increased incidence of bronchitis symptoms from an uncertain pathophysiologic mechanism. Animal data from the 1990s demonstrates that cannabinoid exposure (of which Tetrahydrocannabinol (THC) is an example) results in increased intra-pulmonary oxidative stress indices and immunomodulatory effects resulting in abnormal macrophage function; a finding that may be related the aforementioned symptoms. However, this data is likely now outmoded given the markedly increased (THC) content of today's cannabis for sale (12 percent Tetrahydrocannabinol (THC) compared to 3 percent in the 1990s). Furthermore, most of these findings have not been validated in human subjects. Thus, the investigators hypothesize that habitually smoked cannabis increases intrapulmonary oxidative stress resulting in impaired alveolar macrophage (AM) phagocytosis, elicits an attenuated AM response to pathogen-associated molecular patterns (PAMPs) and promotes AM apoptosis thereby increasing risk of upper and lower airway infections.
II. Background and Significance:
Cannabis use in the United States is rising since legalization for medical and, more recently, recreational purposes. The United Nations Office on Drugs and Crime estimates that in 2012, when cannabis was legal for medical purposes in 17 states, but illegal for recreational consumption nationally, cannabis use among the American population increased from 11.5% to 12.1%. Over the past 2 years, an additional seven states have legalized medical cannabis, and Colorado and Washington have recently legalized its sale for recreational use. Since January 2014, publicly available Colorado data indicate increasing tax revenue from cannabis sales (both medical and recreational), suggesting a rise in state-wide consumption in a relatively short period of time.
Effects of modern inhaled cannabis on lung health are not established. Published epidemiologic data collected prior to the widespread legalization of cannabis and commercialization of the cannabis industry demonstrate consistent associations between "regular" (e.g. near daily) and "heavy" (e.g. for multiple years) cannabis use with poorer lung health. Clinically, regular inhaled cannabis users complain of increased chronic bronchitis symptoms (eg. wheeze, chronic cough) compared to non-smokers; an increased use of medical services for respiratory infections due to immunosuppressive effects of the drug has also been reported. However, characterization of cannabis use in these investigations varies widely, ranging from 7 joint-years (1 joint per day for 1 year) 12 to 117 joint-years in cohorts examined. These studies were also potentially confounded by under-reporting of cannabis use due to the drug's illegal status, and concomitant use of inhaled tobacco in some study populations. Moreover, the quantity of THC in modern cannabis products has been increasing over the past two decades. Therefore, it remains unclear what use patterns of modern inhaled cannabis are harmful to lung health, although more cannabis is being consumed now than ever before, both for medical and recreational purposes. Today, due to the decriminalization of cannabis sale and purchase, the accuracy of self-reported cannabis use is likely much greater than in prior investigations, providing a novel opportunity to more accurately establish patterns of use associated with ill effects on health. Importantly, no study to date has utilized time series analyses, such as the time line follow-back (TLFB), to quantitate the effects of regular cannabis consumption in association with lung health. TLFB techniques are used extensively to quantitate substance use among chronic users of alcohol, tobacco, and more recently, cannabis. TLFB are calendar-assisted, structured interviews that cue memory to enhance accurate recall, and have been determined to be both reliable and valid in quantitating current substance use in detail. TLFB interviews to characterize past 30 day cannabis use have been routinely conducted in research subjects by Dr. Corsi's (co-mentor to Dr. Biehl) research group since 2010, and longer term joint-year data has been collected as well.
Inhaled cannabis use adversely affects function of alveolar macrophages (AMs), critical pulmonary innate immune effectors. AMs express cannabinoid (CB) receptors, primarily CB2, on their surface, whose ligand is THC15 (a cannabinoid). AMs represent the first line of defense against invading pathogens in the lower airways, and function to keep the lungs sterile. Published investigations using AMs isolated via bronchoalveolar lavage (BAL) from small numbers (n<20) of habitual inhaled cannabis users have reported an inappropriately diminished response to S. aureus, an important lung pathogen. When AMs were exposed to S. aureus, they exhibited decreased bacterial phagocytosis and killing; hampered production of the pro-inflammatory cytokines tumor necrosis factor-α, IL-6, and granulocyte monocyte colony stimulating factor; and decreased production of nitric oxide. Preclinical data has suggested that AM viability and apoptosis may also be adversely influenced by THC in a dose- and time-dependent manner through the CB2 receptor, further impairing the AM's ability to respond to pathogens. As mentioned, cannabis use is increasing on a per capita basis, and continues to be used via an inhaled route, while its THC quantity is increasing. Collectively, this suggests the possibility that individuals who regularly use small doses of inhaled cannabis, or have used cannabis for a shorter length of time, may still be at risk for AM dysfunction, clinically manifested by increased respiratory symptoms and an increased risk for pulmonary infections, particularly since pre-clinical data has consistently reported adverse effects of cannabis exposure on infectious disease resistance.
Cannabis exposure in vitro leads to oxidative stress that in turn affects pulmonary cellular viability. Murine lung epithelial cells exposed to cannabis smoke extract in vitro demonstrate a dose-related increase in oxidative stress, while human lung BEAS-2B cells exposed to cannabis smoke extract in vitro display an increase in reactive oxygen species production. Enhanced oxidative stress in each investigation was further associated with evidence of cytotoxicity, characterized by cellular apoptosis and DNA damage. It seems possible, then, that enhanced oxidative stress due to habitual inhaled cannabis may additionally influence the viability and function of AMs in the lower airways. However, the effect of inhaled cannabis on oxidative stress and its relationship to AMs has never been specifically explored with primary cells from human subjects.
In summary, our collaboration will utilize validated methods to characterize regular and chronic cannabis use patterns among exclusive medical and/or recreational cannabis users, in order to examine their impact on cells critical to the maintenance of lung health. Information the investigators derive may be used to counsel active and contemplating cannabis users, and inform medical providers and researchers.
|Study Design||Observational Model: Cohort
Time Perspective: Retrospective
|Target Follow-Up Duration||Not Provided|
|Biospecimen||Retention: Samples With DNA
|Sampling Method||Non-Probability Sample|
|Study Population||Adults aged 18 to 55 who have been exposed to chronic cannabis smoking (without a history of tobacco smoking) and health, non-smoking controls.|
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Original Estimated Enrollment||Same as current|
|Estimated Study Completion Date||May 2023|
|Estimated Primary Completion Date||May 4, 2022 (Final data collection date for primary outcome measure)|
INCLUSION CRITERIA for CANNABIS USING patient: Subjects will be eligible if they meet ALL of the following criteria:
INCLUSION CRITERIA for CONTROL patient: Subjects will be eligible if they meet all of the following:
EXCLUSION CRITERIA for CANNABIS USING patient: Subjects will be ineligible if they meet ANY of the following criteria:
EXCLUSION CRITERIA for CONTROL patient: Subjects will be ineligible to participate if they meet ANY of the following criteria:
|Ages||18 Years to 55 Years (Adult)|
|Accepts Healthy Volunteers||Yes|
|Listed Location Countries||United States|
|Removed Location Countries|
|Other Study ID Numbers||14-1957
UL1TR001082 ( U.S. NIH Grant/Contract )
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||University of Colorado, Denver|
|Study Sponsor||University of Colorado, Denver|
|PRS Account||University of Colorado, Denver|
|Verification Date||March 2019|